Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries
CA 2514794 C · Owner: Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts · Inventors: Krammer, Peter; Demjen, Deana; Martin-Villalba, Ana
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of inhibitors of the CD95 ligand/receptor system for the manufacture of a medicament for the treatment of neurological disorders or injuries in a mammal particularly for the , treatment of spinal cord injury more particularly for the treatment of paraplegia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 10, 2004 and granted May 28, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 10, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 10, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.